EIF2AK3 and melanoma: As an independent method for assessing PERK contribution to melanoma cell survival thereby ensuring that the impact of shRNA was PERK-dependent, we utilized a previously characterized small molecule inhibitor of PERK, GSK2656157 [45–47] or LY-4.